Serum Endocan Levels in Children with Acute Rheumatic Fever.
Journal
Nigerian journal of clinical practice
ISSN: 1119-3077
Titre abrégé: Niger J Clin Pract
Pays: India
ID NLM: 101150032
Informations de publication
Date de publication:
01 Sep 2024
01 Sep 2024
Historique:
received:
08
11
2023
accepted:
21
08
2024
medline:
30
9
2024
pubmed:
30
9
2024
entrez:
30
9
2024
Statut:
ppublish
Résumé
Acute rheumatic fever is an immunologically delayed autoimmune sequel of throat infection caused by group A streptococcus. The aim of this study was to evaluate endocan levels in patients with acute rheumatic fever and compare with the control group. The aim of this study was to evaluate endocan levels in patients with acute rheumatic fever and compare with the control group. Twenty-three children with acute rheumatic fever (11 men, 12 females; mean age 13 ± 2.7 years; range 5 to 15 years) and a healthy control group of 31 children (16 men, 15 females; mean age 13.8 ± 2.4 years; range 5 to 15 years) were recruited. The sedimentation rate, C-reactive protein, antistreptolysin-O titres, and endocan levels were examined in each group. Before anti-inflammatory therapy, endocan levels in the acute rheumatic fever group were not statistically significant to those in the control group, respectively (200.64 ng/L, 120.71 ng/L, P = 0.208). After anti-inflammatory therapy, endocan levels were significantly higher in the acute rheumatic fever group than in the control group, respectively (260.87 ng/L vs. 120.71 ng/L, P < 0.01). A significant difference was found in endocan levels before and after anti-inflammatory therapy in the group of acute rheumatic fever, respectively (200.64 ng/L vs. 260.87 ng/L, P = 0.033). Endocan levels after anti-inflammatory therapy were statistically higher in the severe carditis group compared to those of the mild carditis group, respectively (344.56 ng/L vs. 191.01 ng/L, P < 0.01). Our study showed that serum endocan levels increased during the subacute phase of acute rheumatic fever. We suggest that serum endocan level can be used as a new biomarker to identify the degree of cardiac involvement in acute rheumatic fever.
Sections du résumé
BACKGROUND
BACKGROUND
Acute rheumatic fever is an immunologically delayed autoimmune sequel of throat infection caused by group A streptococcus. The aim of this study was to evaluate endocan levels in patients with acute rheumatic fever and compare with the control group.
AIM
OBJECTIVE
The aim of this study was to evaluate endocan levels in patients with acute rheumatic fever and compare with the control group.
METHODS
METHODS
Twenty-three children with acute rheumatic fever (11 men, 12 females; mean age 13 ± 2.7 years; range 5 to 15 years) and a healthy control group of 31 children (16 men, 15 females; mean age 13.8 ± 2.4 years; range 5 to 15 years) were recruited. The sedimentation rate, C-reactive protein, antistreptolysin-O titres, and endocan levels were examined in each group.
RESULTS
RESULTS
Before anti-inflammatory therapy, endocan levels in the acute rheumatic fever group were not statistically significant to those in the control group, respectively (200.64 ng/L, 120.71 ng/L, P = 0.208). After anti-inflammatory therapy, endocan levels were significantly higher in the acute rheumatic fever group than in the control group, respectively (260.87 ng/L vs. 120.71 ng/L, P < 0.01). A significant difference was found in endocan levels before and after anti-inflammatory therapy in the group of acute rheumatic fever, respectively (200.64 ng/L vs. 260.87 ng/L, P = 0.033). Endocan levels after anti-inflammatory therapy were statistically higher in the severe carditis group compared to those of the mild carditis group, respectively (344.56 ng/L vs. 191.01 ng/L, P < 0.01).
CONCLUSION
CONCLUSIONS
Our study showed that serum endocan levels increased during the subacute phase of acute rheumatic fever. We suggest that serum endocan level can be used as a new biomarker to identify the degree of cardiac involvement in acute rheumatic fever.
Identifiants
pubmed: 39348324
doi: 10.4103/njcp.njcp_783_23
pii: 01253091-202427090-00003
doi:
Substances chimiques
ESM1 protein, human
0
Proteoglycans
0
Neoplasm Proteins
0
Biomarkers
0
C-Reactive Protein
9007-41-4
Antistreptolysin
9006-92-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1051-1056Informations de copyright
Copyright © 2024 Copyright: © 2024 Nigerian Journal of Clinical Practice.
Références
Carapetis JR, Currie BJ, Mathews JD. Cumulative incidence of rheumatic fever in an endemic region: A guide to the susceptibility of the population? Epidemiol Infect 2000;124:239–44.
Carapetis JR. Rheumatic heart disease in developing countries. N Engl J Med 2007;357:439–41.
Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): A potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006;1765:25-37.
Bèchard D, Scherpereel A, Hammad H, Gentina T, Tsicopoulos A, Aumercier M, et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 2001;167:3099-106.
Voiosu T, Balanescu P, Bengu A, Voiosu A, Baicuş CR, Barbu M, et al. Serum endocan levels are increased in patients with inflammatory bowel disease. Clin Lab 2014;60:505-10.
Balta I, Balta S, Koryurek OM, Demirkol S, Mikhailidis DP, Celik T, et al. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol 2014;70:291-6.
Omma A, Armağan B, Güven SC, Sandıkçı SC, Çolak S, Yücel Ç, et al. Endocan: A novel marker for colchicine resistance in familial mediterranean fever patients? Front Pediatr 2021;9:788864.
Yımaz Y, Durmuş RB, Saraçoğlu B, Şahin S, Adrovic A, Barut K, et al. The assessment of serum endocan levels in children with juvenile idiopathic arthritis. Arch Rheumatol 2018;33:168-73.
Gewitz MH, Baltimore RS, Tani LY, Sable CA, Shulman ST, Carapetis J, et al. Revision of the Jones criteria for the diagnosis of the rheumatic fever in the era of Doppler echocardiography: A scientific statement of the American Heart Association. Circulation 2015;131:1806-18.
Tani LY. Rheumatic fever and rheumatic heart disease. In: Allen HD, Driscoll DJ, Shaddy RE, Feltes TF, editors. Moss and Adam’s Heart Disease in Infants, Children and Adolescents. 10th ed. Philadelphia: Lippincott Williams and Wilkins; 2020. p. 1256–80.
Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardio-graphic measurements. Circulation 1978;58:1072–83.
Takamoto S, Kyo S, Adachi H, Matsumura M, Yokote Y, Omoto R. Intraoperative color flow mapping by real-time two-dimensional Doppler echocardiography for evaluation of valvular and congenital heart disease and vascular disease. J Thorac Cardiovasc Surg 1985;90:802–12.
Wu YT, Chang AC, Chin AJ. Semiquantitative assess- ment of mitral regurgitation by Doppler color flow ima- ging in patients aged <20 years. Am J Cardiol 1993;71:727–32.
Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 1996;271:20458–64.
Yilmaz MI, Siriopol D, Saglam M, Kurt YG, Unal HU, Eyileten T, et al. Plasma endocanlevels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int 2014;86:1213–20.
Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Celik T, Iyisoy A. Endocan: A novel inflammatory indicator in cardiovascular disease? Atherosclerosis 2015;243:339–43.
Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Kurtoglu E, Demir M, et al. Endocan-a novel inflammatory indicator in newly diagnosed patients with hypertension: A pilot study. Angiology 2014;65:773–7.
Kemeny E, Grieve T, Marcus R, Sareli P, Zabriskie JB. Identification of mononuclear cells and T cell subsets in rheumatic valvulitis. Clin Immunol Immunopathol 1989;52:225–37.
Narula J, Chopra P, Talwar KK, Reddy KS, Vasan RS, Tandon R, et al. Does endomyocardial biopsy aid in the diagnosis of active rheumatic carditis? Circulation 1993;88:2198–205.
Kumar V, Ganguly NK, Sethi AK, Anand IS, Verma J, Wahi PL. Role of oxygen free radicals generated by blood monocytes and neutrophils in the pathogenesis of rheumatic fever and rheumatic heart disease. J Mol Cell Cardiol 1990;22:645–51.
Oran B, Atabek E, Karaaslan S, Reisli Y, Gültekin F, Erkul Y. Oxygen free radicals in children with acute rheumatic fever. Cardiol Young 2001;11:285–8.
Yegin O, Coskun M, Ertug H. Cytokines in acute rheumatic fever. Eur J Pediatr 1997;156:25–9.
Kutukculer N, Narin N. Plasma interleukin-7 (IL-7) and IL-8 concentrations in acute rheumatic fever and chronic rheumatic heart disease. Scand J Rheumatol 1995;24:383–5.
Narin N, Kutukculer N, Ozyurek R, Bakiler AR, Parlar A, Arcasoy M. Lymphocyte subsets and plasma IL-1 alpha, IL-2, and TNF-alpha concentrations in acute rheumatic fever and chronic rheumatic heart disease. Clin Immunol Immunopathol 1995;77:172–6.
Uner A, Sal E, Dogan M, Sanli FM, Acikgoz M, Cemek M, et al. Investigation of oxidant and antioxidant pathway changes in acute rheumatic fever. Acta Cardiol 2010;65:53–7.
Chiu-Braga YY, Hayashi SY, Schafranski M, Messias-Reason IJ. Further evidence of inflammation in chronic rheumatic valve disease (CRVD): High levels of advanced oxidation protein products (AOPP) and high sensitive C-reactive protein (hs-CRP). Int J Cardiol 2006;109:275–6.